Stifel analyst W. Andrew Carter, in a first reaction note ahead of Aurora Cannabis' earnings call, said he expects the shares to be under significant pressure today given that its Q4 net sales of C$98.9M missed his estimate and the company's preliminary guidance range offered last month. He believes the investment demands and convertible debt coming due in the first quarter of calendar 2020 will necessitate Aurora come to the capital markets "for a significant ask" for funding, added Carter, who expects the elevated financing risk to weigh on the stock. He keeps a Hold rating on Aurora Cannabis shares.

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here